Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015;122:146-52)

Ophthalmology

Volumn 123, Issue 2, 2016, Pages e14-e16

  Avery, Robert L ^a  

^a California Retina Consultants and Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

AGE RELATED MACULAR DEGENERATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; FOLLOW UP; HEART INFARCTION; HUMAN; LETTER; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYSTEMIC DISEASE; FEMALE; MALE; WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; WET MACULAR DEGENERATION;

EID: 84961924620     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.08.031     Document Type: Letter

References (5)

1. K. Berg, T.R. Pedersen, L. Sandvik, and R. Bragadóttir Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol Ophthalmology 122 2015 146 152
2. S.D. Solomon, K. Lindsley, S.S. Vedula, and et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration Cochrane Database Syst Rev 8 2014 CD005139
3. L. Moja, E. Lucenteforte, K.H. Kwag, and et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration Cochrane Database Syst Rev 9 2014 CD011230
4. J.F. Korobelnik, D.V. Do, U. Schmidt-Erfurth, and et al. Intravitreal aflibercept for diabetic macular edema Ophthalmology 121 2014 2247 2254
5. R.L. Avery, A.A. Castellarin, N.C. Steinle, and et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD Br J Ophthalmol 98 2014 1636 1641